Cargando…
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
FLT3 mutations are one of the most common genetic alterations in acute myeloid leukemia (AML) and are identified in approximately one-third of newly diagnosed patients. Aberrant FLT3 receptor signaling has important implications for the biology and clinical management of AML. In recent years, target...
Autores principales: | Ge, Shuai-Shuai, Liu, Song-Bai, Xue, Sheng-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515417/ https://www.ncbi.nlm.nih.gov/pubmed/36185253 http://dx.doi.org/10.3389/fonc.2022.996438 |
Ejemplares similares
-
CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023) -
FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018) -
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
por: Kennedy, Vanessa E., et al.
Publicado: (2020) -
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate
por: Klement, Laura, et al.
Publicado: (2023) -
The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells
por: Lu, Xiyuan, et al.
Publicado: (2021)